ABIOMED (ABMD) Hits New 12-Month High at $226.12
ABIOMED, Inc. (NASDAQ:ABMD) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $226.12 and last traded at $224.13, with a volume of 535100 shares trading hands. The stock had previously closed at $218.09.
Several brokerages recently issued reports on ABMD. Jefferies Group upped their target price on ABIOMED to $250.00 and gave the company a “buy” rating in a research report on Friday, January 12th. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday, January 11th. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $213.00 target price on the stock in a research report on Friday, December 29th. Piper Jaffray Companies reiterated a “buy” rating on shares of ABIOMED in a research note on Thursday, January 4th. Finally, SunTrust Banks reiterated a “buy” rating and set a $195.00 price target on shares of ABIOMED in a research note on Wednesday, November 1st. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $199.67.
The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02. The stock has a market cap of $10,030.00, a P/E ratio of 110.41, a price-to-earnings-growth ratio of 2.88 and a beta of 0.15.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.38 by $0.16. The business had revenue of $132.80 million for the quarter, compared to the consensus estimate of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The company’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.20 EPS. research analysts expect that ABIOMED, Inc. will post 2.41 earnings per share for the current year.
In other news, Director Dorothy E. Puhy sold 6,364 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $179.08, for a total value of $1,139,665.12. Following the sale, the director now owns 39,532 shares in the company, valued at $7,079,390.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Michael G. Howley sold 10,000 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $178.64, for a total value of $1,786,400.00. Following the completion of the sale, the vice president now owns 56,757 shares in the company, valued at approximately $10,139,070.48. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently modified their holdings of ABMD. Seven Eight Capital LP purchased a new stake in shares of ABIOMED in the second quarter worth about $100,000. Crow Point Partners LLC purchased a new stake in shares of ABIOMED in the fourth quarter worth about $120,000. Rehmann Capital Advisory Group purchased a new stake in shares of ABIOMED in the third quarter worth about $202,000. Sigma Planning Corp purchased a new stake in shares of ABIOMED in the third quarter worth about $206,000. Finally, Dorsey & Whitney Trust CO LLC purchased a new stake in shares of ABIOMED in the third quarter worth about $215,000. Hedge funds and other institutional investors own 90.75% of the company’s stock.
TRADEMARK VIOLATION WARNING: “ABIOMED (ABMD) Hits New 12-Month High at $226.12” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/abiomed-abmd-hits-new-12-month-high-at-226-12/1812549.html.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.